News
Return of FDA official targeted by Trump allies hits biotech shares
Sarepta shares dropped as much as 5.2 per cent on Monday amid volatile trading, while those of Replimune — another gene therapy group — fell as much as 15.1 per cent. Replimune has a drug pending approval before the FDA division Prasad oversees. The declines eroded some of the gains the stocks experienced following his departure.
Vinay Prasad is once again head of the FDA’s Center for Biologics Evaluation and Research, after Laura Loomer led a campaign ...
Dr. Vinay Prasad is resuming leadership of the FDA center that regulates vaccines and biotech therapies, a spokesperson for ...
Vinay Prasad, the U.S. Food and Drug Administration's top vaccine regulator, is returning to his post less than two weeks ...
Vinay Prasad, a professor who until earlier this year headed a cancer-drugs and health-policy lab at UC San Francisco, ...
Plus more pharma news from the Pharmalittle newsletter.
9h
Trump’s first term also had an enduring impact on the courts, appointing 234 judges. By the end of that term, more than ...
The U.S. Food and Drug Administration on Thursday announced a new program to speed up construction and review of drug ...
Vinay Prasad’s ouster as the Food and Drug Administration’s top vaccine and gene therapy regulator came after frustration ...
A spokesperson for the Health Department has said that Vinay Prasad did not want to be a "distraction to the great work of ...
The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere to ...
In an interview taped before Trump announced his Friday summit with Russian President Vladimir Putin over Russia’s war with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback